Inamo, J., Keegan, J., Griffith, A., Ghosh, T., Horisberger, A., Howard, K., Pulford, J. F., Murzin, E., Hancock, B., Dominguez, S. T., Gurra, M. G., Gurajala, S., Jonsson, A. H., Seifert, J. A., Feser, M. L., Norris, J. M., Cao, Y., Apruzzese, W., Bridges, S. L., … Zhang, F. (2025). Deep immunophenotyping reveals circulating activated lymphocytes in individuals at risk for rheumatoid arthritis. Journal of Clinical Investigation, 135(6). https://doi.org/10.1172/jci185217

Kang, J. S., Andrews, H. F., Giles, J. T., Liao, K. P., Solomon, D. H., & Bathon, J. M. (2024). Returning Incidental Research Findings From 18F‐Fluorodeoxyglucose–Positron Emission Tomography/Computed Tomography to Participants: A Survey of Investigators From a Clinical Trial of Rheumatoid Arthritis. Arthritis Care & Research, 76(12), 1637–1646. Portico. https://doi.org/10.1002/acr.25424

Liao, K. P., Rist, P., Giles, J., Santacroce, L., Connelly, M. A., Glynn, R. J., Ridker, P., Tawakol, A., Bathon, J., & Solomon, D. H. (2024). Impact of RA treatment strategies on lipids and vascular inflammation in rheumatoid arthritis: a secondary analysis of the TARGET randomized active comparator trial. Arthritis Research & Therapy, 26(1). https://doi.org/10.1186/s13075-024-03352-3

Thomas, M. A., Naik, P., Wang, H., Giles, J. T., Girgis, A. A., Kim, S.-Y., Johnson, T. P., Curran, A. M., Crawford, J. D., Jahanbani, S., Bingham, C. O., Robinson, W. H., Na, C. H., & Darrah, E. (2024). The monocyte cell surface is a unique site of autoantigen generation in rheumatoid arthritis. Proceedings of the National Academy of Sciences, 121(17). https://doi.org/10.1073/pnas.2304199121

Buch, M. H., Bhatt, D. L., Charles-Schoeman, C., Giles, J. T., Mikuls, T., Koch, G. G., Ytterberg, S., Nagy, E., Jo, H., Kwok, K., Connell, C. A., Masri, K. R., & Yndestad, A. (2024). Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study. RMD Open, 10(2), e003912. https://doi.org/10.1136/rmdopen-2023-003912

Solomon, D. H., Demler, O., Rist, P. M., Santacroce, L., Tawakol, A., Giles, J. T., Liao, K. P., & Bathon, J. M. (2024). Biomarkers of Cardiovascular Risk in Patients With Rheumatoid Arthritis: Results From the TARGET Trial. Journal of the American Heart Association, 13(5). https://doi.org/10.1161/jaha.123.032095

Park, E., & Bathon, J. (2024). Cardiovascular complications of rheumatoid arthritis. Current Opinion in Rheumatology, 36(3), 209–216. https://doi.org/10.1097/bor.0000000000001004

Straube, J., Bukhari, S., Lerrer, S., Winchester, R. J., Gartshteyn, Y., Henick, B. S., Dragovich, M. A., & Mor, A. (2024). PD-1 signaling uncovers a pathogenic subset of T cells in inflammatory arthritis. Arthritis Research & Therapy, 26(1). https://doi.org/10.1186/s13075-023-03259-5

Zureigat, H., Civieri, G., Abohashem, S., Osborne, M. T., Solomon, D. H., Giles, J. T., Bathon, J., Massarotti, E., Unizony, S., & Tawakol, A. (2024). Improvement in joint inflammation is accompanied by reduction in arterial inflammation: Tocilizumab in rheumatoid arthritis. Journal of Nuclear Cardiology, 33, 101813. https://doi.org/10.1016/j.nuclcard.2024.101813

Nussdorf, A., Park, E., Amigues, I., Geraldino-Pardilla, L., Bokhari, S., Giles, J. T., & Bathon, J. M. (2024). Associations of galectin-3 levels with measures of vascular disease in patients with rheumatoid arthritis. Seminars in Arthritis and Rheumatism, 65, 152357. https://doi.org/10.1016/j.semarthrit.2023.152357

Baker, J. F., ODell, J. R., England, B. R., Giles, J. T., Newcomb, J. A., George, M. D., Thiele, G., Moreland, L., Bridges, S. L., Curtis, J. R., & Mikuls, T. R. (2024). Lower body mass and lower adiposity are associated with differential responses to two treatment strategies for rheumatoid arthritis. Annals of the Rheumatic Diseases, 83(4), 429–436. https://doi.org/10.1136/ard-2023-225014

Mehta, B., Goodman, S., DiCarlo, E., Jannat-Khah, D., Gibbons, J. A. B., Otero, M., Donlin, L., Pannellini, T., Robinson, W. H., Sculco, P., Figgie, M., Rodriguez, J., Kirschmann, J. M., Thompson, J., Slater, D., Frezza, D., Xu, Z., Wang, F., & Orange, D. E. (2023). Machine learning identification of thresholds to discriminate osteoarthritis and rheumatoid arthritis synovial inflammation. Arthritis Research & Therapy, 25(1). https://doi.org/10.1186/s13075-023-03008-8

Wang, J., Li, J., Kramer, S. T., Su, L., Chang, Y., Xu, C., Eadon, M. T., Kiryluk, K., Ma, Q., & Xu, D. (2023). Dimension-agnostic and granularity-based spatially variable gene identification using BSP. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-43256-5

Bathon, J. M., Centola, M., Liu, X., Jin, Z., Ji, W., Knowlton, N. S., Ferraz-Amaro, I., Fu, Q., Giles, J. T., Wasko, M. C., Stein, C. M., & Van Eyk, J. E. (2023). Identification of novel biomarkers for the prediction of subclinical coronary artery atherosclerosis in patients with rheumatoid arthritis: an exploratory analysis. Arthritis Research & Therapy, 25(1). https://doi.org/10.1186/s13075-023-03196-3

Zhang, F., Jonsson, A. H., Nathan, A., Millard, N., Curtis, M., Xiao, Q., Gutierrez-Arcelus, M., Apruzzese, W., Watts, G. F. M., Weisenfeld, D., Nayar, S., Rangel-Moreno, J., Meednu, N., Marks, K. E., Mantel, I., Kang, J. B., Rumker, L., Mears, J., … Slowikowski, K. (2023). Deconstruction of rheumatoid arthritis synovium defines inflammatory subtypes. Nature, 623(7987), 616–624. https://doi.org/10.1038/s41586-023-06708-y

Di Matteo, A., Bathon, J. M., & Emery, P. (2023). Rheumatoid arthritis. The Lancet, 402(10416), 2019–2033. https://doi.org/10.1016/s0140-6736(23)01525-8

Kaplan, J., Askanase, A., Chu, D., Abdellatif, A., Basu, D., & Mirsaeidi, M. (2023). Acthar® Gel Treatment for Patients with Autoimmune and Inflammatory Diseases: An Historical Perspective and Characterization of Clinical Evidence. Clinical Drug Investigation, 43(10), 739–761. https://doi.org/10.1007/s40261-023-01303-5

Schanberg, L. E., Mulugeta, L. (Yeruk), Akinlade, B., Brunner, H. I., Chen, J., Colbert, R. A., Delgaizo, V., Gastonguay, M. R., Glaser, R., Imundo, L., Lovell, D. J., Leu, J. H., Mostafa, N. M., Nelson, R. M., Nigrovic, P. A., Nikolov, N. P., Rider, L. G., Rothwell, R., Sahajwalla, C., … Yao, L. (2023). Therapeutic Development in Polyarticular Course Juvenile Idiopathic Arthritis: Extrapolation, Dose Selection, and Clinical Trial Design. Arthritis & Rheumatology, 75(10), 1856–1866. Portico. https://doi.org/10.1002/art.42534

Bergman, D., Roelstraete, B., Sun, J., Ebrahimi, F., Askling, J., & Ludvigsson, J. F. (2023). Microscopic colitis and risk of incident rheumatoid arthritis: A nationwide population‐based matched cohort study. Alimentary Pharmacology & Therapeutics, 58(10), 1028–1040. Portico. https://doi.org/10.1111/apt.17708

Weber, B. N., Giles, J. T., & Liao, K. P. (2023). Shared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease. Nature Reviews Rheumatology, 19(7), 417–428. https://doi.org/10.1038/s41584-023-00969-7

Solomon, D. H., Giles, J. T., Liao, K. P., Ridker, P. M., Rist, P. M., Glynn, R. J., Broderick, R., Lu, F., Murray, M. T., Vanni, K., Santacroce, L. M., Abohashem, S., Robson, P. M., Fayad, Z., Mani, V., Tawakol, A., & Bathon, J. (2022). Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 82(3), 324–330. https://doi.org/10.1136/ard-2022-223302

Yao, M., Huang, X., Guo, Y., Zhao, J. V., & Liu, Z. (2023). Disentangling the common genetic architecture and causality of rheumatoid arthritis and systemic lupus erythematosus with COVID‐19 outcomes: Genome‐wide cross trait analysis and bidirectional Mendelian randomization study. Journal of Medical Virology, 95(2). Portico. https://doi.org/10.1002/jmv.28570

Smolen, J. S., Landewé, R. B. M., Bergstra, S. A., Kerschbaumer, A., Sepriano, A., Aletaha, D., Caporali, R., Edwards, C. J., Hyrich, K. L., Pope, J. E., de Souza, S., Stamm, T. A., Takeuchi, T., Verschueren, P., Winthrop, K. L., Balsa, A., Bathon, J. M., Buch, M. H., Burmester, G. R., … van der Heijde, D. (2022). EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Annals of the Rheumatic Diseases, 82(1), 3–18. https://doi.org/10.1136/ard-2022-223356

Charles-Schoeman, C., Buch, M. H., Dougados, M., Bhatt, D. L., Giles, J. T., Ytterberg, S. R., Koch, G. G., Vranic, I., Wu, J., Wang, C., Kwok, K., Menon, S., Rivas, J. L., Yndestad, A., Connell, C. A., & Szekanecz, Z. (2022). Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Annals of the Rheumatic Diseases, 82(1), 119–129. https://doi.org/10.1136/ard-2022-222259

Doyle, J. B., Lebwohl, B., Askling, J., Forss, A., Green, P. H. R., Roelstraete, B., Söderling, J., & Ludvigsson, J. F. (2022). Risk of Juvenile Idiopathic Arthritis and Rheumatoid Arthritis in Patients With Celiac Disease: A Population-Based Cohort Study. American Journal of Gastroenterology, 117(12), 1971–1981. https://doi.org/10.14309/ajg.0000000000002014

Ferraz-Amaro, I., Sheikh, A., Polack, B., Giles, J. T., & Bathon, J. M. (2022). Articular18Fluorodeoxyglucose Uptake Is Associated With Clinically Assessed Swollen Joint Count in Patients With Rheumatoid Arthritis. The Journal of Rheumatology, 49(12), 1315–1319. https://doi.org/10.3899/jrheum.220231

Park, E., Ito, K., Iqbal, R., Amigues, I., Bokhari, S., Van Eyk, J., Depender, C., Giles, J. T., & Bathon, J. (2022). Prospective changes in diastolic function in patients with rheumatoid arthritis. Arthritis Research & Therapy, 24(1). https://doi.org/10.1186/s13075-022-02864-0

Gómez‐Bañuelos, E., Shi, J., Wang, H., Danila, M. I., Bridges, S. L., Giles, J. T., Sims, G. P., Andrade, F., & Darrah, E. (2022). Heavy Chain Constant Region Usage in Antibodies to Peptidylarginine Deiminase 4 as a Marker of Disease Subsets in Rheumatoid Arthritis. Arthritis & Rheumatology, 74(11), 1746–1754. Portico. https://doi.org/10.1002/art.42262

Padem, N., Wright, H., Fuleihan, R., Garabedian, E., Suez, D., Cunningham-Rundles, C., Marsh, R. A., & Khojah, A. (2022). Rheumatologic diseases in patients with inborn errors of immunity in the USIDNET registry. Clinical Rheumatology, 41(7), 2197–2203. https://doi.org/10.1007/s10067-021-06044-4

White, I. R., Kleinstein, S. E., Praet, C., Chamberlain, C., McHale, D., Maia, J. M., Xie, P., Goldstein, D. B., Urban, T. J., & Shea, P. R. (2022). A genome-wide screen for variants influencing certolizumab pegol response in a moderate to severe rheumatoid arthritis population. PLOS ONE, 17(4), e0261165. https://doi.org/10.1371/journal.pone.0261165